Azul Optics - a BVI Spin-out
8 November 2016
Age-related macular degeneration (AMD) is the leading cause of incurable blindness in the western world.
By 2020, it is predicted that nearly 200 million people worldwide will suffer from AMD. Azul Optics is developing a device that can rapidly assess a risk factor for AMD – macular pigment density, making it easy to integrate macular pigment density screening into regular eye exams.
The novel approach stems from nearly a decade of vision research conducted by inventor and Chief Technical Officer of Azul Optics, Dr Shelby Temple, in BVI. The company has raised substantial funding to support a large-scale clinical study as well as further development of the product. The goal is to introduce technology that enables eye health professionals to focus on AMD prevention. http://azuloptics.com/